who is developing retatrutide ADA 2026: Revolution Retatrutide—A Game Changer in Obesity

Best case: approval around mid-2027

doi: 10.1002/acr2.70103

Semaglutide's extended half-life of approximately one week allows for once-weekly subcutaneous administration (Ozempic and Wegovy) or daily oral dosing (Rybelsus)

The combination of caloric deficit from medication with muscle-building stimulus from strength training shifts body composition favorably toward fat loss while maintaining lean tissue

Key Takeaways Nausea is one of the most common side effects of GLP-1 medications and is usually most noticeable when starting treatment or increasing your dose

Do not attempt to self-treat cardiac symptoms with supplements alone